Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:ABT
CUSIP00282410
Phone224-667-6100
Debt
Debt-to-Equity Ratio0.64
Current Ratio1.58
Quick Ratio1.16
Price-To-Earnings
Trailing P/E Ratio25.98
Forward P/E Ratio22.48
P/E Growth1.81
Sales & Book Value
Annual Sales$27.39 billion
Price / Sales4.15
Cash Flow$4.7892 per share
Price / Cash13.52
Book Value$17.87 per share
Price / Book3.62
Profitability
EPS (Most Recent Fiscal Year)$2.50
Net Income$477 million
Net Margins3.13%
Return on Equity15.30%
Return on Assets6.68%
Miscellaneous
Employees99,000
Outstanding Shares1,754,320,000
Market Cap$113.54 billion
Abbott Laboratories (NYSE:ABT) Frequently Asked Questions
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories announced a quarterly dividend on Friday, June 8th. Investors of record on Friday, July 13th will be given a dividend of $0.28 per share on Wednesday, August 15th. This represents a $1.12 annualized dividend and a yield of 1.73%. The ex-dividend date of this dividend is Thursday, July 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) issued its earnings results on Wednesday, July, 18th. The healthcare product maker reported $0.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.71 by $0.02. The healthcare product maker had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.71 billion. Abbott Laboratories had a net margin of 3.13% and a return on equity of 15.30%. The company's revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.62 earnings per share. View Abbott Laboratories' Earnings History.
When is Abbott Laboratories' next earnings date?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories updated its FY18 earnings guidance on Wednesday, July, 18th. The company provided EPS guidance of $2.85-2.91 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.86. Abbott Laboratories also updated its Q3 guidance to $0.73-0.75 EPS.
What price target have analysts set for ABT?
18 brokerages have issued 12 month price targets for Abbott Laboratories' shares. Their predictions range from $64.00 to $80.00. On average, they expect Abbott Laboratories' stock price to reach $69.75 in the next twelve months. This suggests a possible upside of 7.7% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.
What is the consensus analysts' recommendation for Abbott Laboratories?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Mr. Miles D. White, Chairman & CEO (Age 63)
- Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 48)
- Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 52)
- Mr. Robert B. Ford, Exec. VP of Medical Devices (Age 44)
- Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 39)
Has Abbott Laboratories been receiving favorable news coverage?
News headlines about ABT stock have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Abbott Laboratories earned a news impact score of 0.20 on Accern's scale. They also assigned press coverage about the healthcare product maker an impact score of 47.42 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Abbott Laboratories.
Who are Abbott Laboratories' major shareholders?
Abbott Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.62%), Massachusetts Financial Services Co. MA (2.23%), Bank of New York Mellon Corp (1.65%), Morgan Stanley (1.21%), Janus Henderson Group PLC (0.78%) and Macquarie Group Ltd. (0.68%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Pederson, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Which major investors are selling Abbott Laboratories stock?
ABT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bank of New York Mellon Corp, Assenagon Asset Management S.A., Massachusetts Financial Services Co. MA, Redmile Group LLC, CIBC World Markets Inc., Natixis and Partner Fund Management L.P.. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Jaime Contreras, Jared Watkin, Michael J Pederson, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Which major investors are buying Abbott Laboratories stock?
ABT stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Charles Schwab Investment Advisory Inc., American Century Companies Inc., BlackRock Inc., Swedbank, Janus Henderson Group PLC, Bank of Nova Scotia and Cornerstone Wealth Management LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Daniel J Starks, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.
How do I buy shares of Abbott Laboratories?
Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of ABT stock can currently be purchased for approximately $64.75.
How big of a company is Abbott Laboratories?
Abbott Laboratories has a market capitalization of $113.54 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.
How can I contact Abbott Laboratories?
Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
